(24/7 MARKET NEWS) – OraSure Technologies, Inc. (NASDAQ: OSUR) reported, after yesterday’s market close, fourth quarter 2022 financial results. Highlights include InteliSwab quarterly revenue of $88.9 million, up 12% sequentially; two new federal government contracts extending InteliSwab’s revenue tail; Quest Diagnostics Genomic Sequencing Services deal for saliva collection kits; restructuring expected to result in $15 million operating expense savings; and cash balance grew by $9 million to $111 million, over prior quarter
OraSure Technologies is at $5.60, up $0.67 (13.59%), on trading volume of 20 thousand premarket shares.
Its 52-week trading range is $2.62 to $8.79. If it can trade above $5.90, on much stronger volume, it may challenge its April trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
